Algernon Pharmaceuticals (CNSX:AGN) is one of the few companies aiming to develop the classic psychedelic N,N-Dimethyltryptamine (DMT). Most recently, the company’s Algernon NeuroScience announced its plans to explore DMT as a treatment for traumatic brain injury (TBI). The company plans on launching a Phase 2 study in the fourth quarter of 2023 to test its…